In addition to funding accomplished scientists in pancreatic cancer research, the Foundation is attracting new researchers to the field including David Sabatini, M.D., Ph.D., Whitehead Institute for Biomedical Research, and David Pellman, M.D., Dana-Farber Cancer Institute.
Lustgarten Foundation research investigators are charged with advancing the study of pancreatic cancer that will lead to earlier detection methods, personalized medicine, and new and effective therapies. Various approaches including immunotherapy, cancer genetics, epigenetics, and cancer metabolism will be used to achieve very specific outcomes.
Core to the Foundation's research strategy is funding a dedicated pancreatic cancer research laboratory at the Cold Spring Harbor Laboratory.
The Foundation's new Translational Clinical Program is funding programs at Columbia University Medical Center, Dana-Farber Cancer Institute, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine with the goal of moving biology into the clinic.
The Lustgarten Foundation is a private foundation dedicated to funding pancreatic cancer research. The Foundation supports research to find a cure for pancreatic cancer, facilitates dialogue within the medical and scientific community, and educates the public about the disease through awareness campaigns and fundraising events. Since its inception, it has directed USD 154m to research.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval